GDF15 and GFRAL: The Mechanistic Case for a New Therapeutic Target

Growth/differentiation factor 15 (GDF15) is the most specifically and frequently discussed therapeutic target in the hyperemesis gravidarum (HG) research landscape, supported by converging lines of biomarker, genetic, and neuroanatomical evidence. GDF15 is secreted by trophoblast and decidual stromal cells during pregnancy; its receptor, GFRAL, is expressed exclusively in the hindbrain area postrema and nucleus tractus solitarius — the neuroanatomical substrate of nausea and emesis circuits — providing a direct mechanistic link between placental signalling and central emetic drive.

The quantitative case for GDF15 as a causal driver comes from the Cambridge Baby Growth Study (University of Cambridge / Wellcome Trust-MRC Institute of Metabolic Science, 2017), which enrolled 791 pregnant women and directly measured GDF15 concentrations across symptom strata. Women reporting second-trimester vomiting had a geometric mean GDF15 of 11,670 pg/mL — significantly higher than asymptomatic pregnant controls — and concentrations were further elevated in women requiring antiemetic pharmacotherapy. This dose-dependent relationship between circulating GDF15 and clinical severity suggests that even partial attenuation of GDF15 signalling could produce measurable anti-emetic benefit, a critical criterion for therapeutic target validation.

Genetic evidence from the David Geffen School of Medicine at UCLA (2018) reinforces the causal interpretation. A familial study using exome-sequencing data from five HG families demonstrated that GDF15 overexpression alleles segregate with disease and that the GDF15 risk allele rs16982345 is associated with HG recurrence. Given that HG recurs in approximately 80% of affected women, this heritable overexpression signal has substantial clinical relevance. A 2022 comprehensive review from Henan University further positions GDF15 as a priority target for precision therapeutic development, situating it within a broader history of pathogenic hypotheses — hormonal factors, Helicobacter pylori, gastrointestinal dysmotility, and psychosocial factors — that have not yielded targeted therapies.

“GDF15 overexpression alleles segregate with disease in HG families, and the risk allele rs16982345 is associated with HG recurrence — which occurs in approximately 80% of affected women.”

The therapeutic implications are twofold: the GFRAL receptor’s hindbrain-exclusive expression makes it an anatomically tractable target for receptor-level blockade, while GDF15’s role as a circulating ligand makes it amenable to neutralisation via monoclonal antibody. Both ligand neutralisation (anti-GDF15 antibody) and receptor blockade (anti-GFRAL antibody or small molecule) are mechanistically supported by the retrieved dataset. No HG-specific patent filings describing such agents were retrieved, signalling that the commercial IP landscape for GDF15-targeted HG therapy is either early-stage or concentrated in patent families not yet captured — a due diligence gap of significance for IP strategists.

Current Pharmacotherapy: Symptomatic, Restricted, and Evidence-Poor

The backbone of current HG pharmacotherapy — ondansetron and metoclopramide — operates through symptomatic mechanisms with no direct engagement of the GDF15/GFRAL axis, and the evidence base for both agents in HG specifically remains limited. A 2022 meta-analysis from the Hashemite University pooled five randomised controlled trials (n=695) comparing ondansetron versus metoclopramide, providing the most rigorous comparative data currently available for the two most commonly prescribed antiemetics in HG.

Ondansetron (5-HT3 Antagonist)

Ondansetron is the most extensively discussed pharmacological antiemetic for HG in the retrieved dataset. Its mechanism — blockade of the serotonin 5-HT3 receptor — is well established in chemotherapy-induced nausea and vomiting, and its use in HG has expanded following European Medicines Agency (EMA) restrictions on metoclopramide in 2013. A Norwegian retrospective cohort study (2002–2019, n=1,064 hospitalised HG patients) from Haukeland University Hospital documents this prescribing shift in real-world practice. Ondansetron is currently being formally evaluated as an active comparator in the VOMIT trial alongside mirtazapine, with PUQE (Pregnancy Unique Quantification of Emesis) score as the primary validated outcome measure.

Metoclopramide (Dopamine D2 Antagonist) and CYP2D6 Pharmacogenomics

Metoclopramide remains widely used despite EMA safety restrictions limiting its use to a maximum of five days, introduced in 2013 following concerns about extrapyramidal adverse effects. Research from the University of Otago (2019) has identified a clinically actionable pharmacogenomic signal: CYP2D6 poor metabolizer status significantly increases the risk of metoclopramide-induced acute dystonia in pregnant women, compounded by estrogen-mediated augmentation of dopamine sensitivity. This finding has immediate clinical implementation potential — genotyping for CYP2D6 prior to metoclopramide prescription could reduce acute dystonia risk in HG patients without requiring new drug development.

Corticosteroids

A systematic review and meta-analysis from Academic Medical Center Amsterdam (2015) evaluated corticosteroids in HG across five RCTs (n=310), finding no significant effect on readmission rates. Two small trials reported reduced vomiting episodes. A completed RCT from Sharif Medical and Dental College (n=300) compared prednisolone 20 mg twice daily versus placebo and provides the largest direct evidence base for this modality. Meta-analysis results were generally underpowered for definitive conclusions on perinatal outcomes. Corticosteroids remain off-label in HG with a limited and inconclusive evidence base.

Emerging Modalities: Mirtazapine, Cannabinoids, and Biomarker-Guided Approaches

Beyond established antiemetics, three emerging modalities are advancing through the HG evidence base: mirtazapine in a formal placebo-controlled trial, cannabinoids in observational data with mechanistic support, and ADAMTS-1 as a novel biomarker candidate linked to trophoblastic invasion pathways.

Mirtazapine and the VOMIT Trial

Mirtazapine — a noradrenergic and specific serotonergic antidepressant (NaSSA) — is under active clinical evaluation in the VOMIT trial (Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum), an NCT-registered randomised double-blind placebo-controlled multicentre trial across eight Danish hospitals with a planned enrolment of 180 participants. Mechanistically, mirtazapine is hypothesised to reduce emesis through its H1-antihistamine and 5-HT3 antagonist properties, and its investigation follows case reports in refractory HG. The VOMIT trial represents the first placebo-controlled RCT evaluating mirtazapine in HG and is the most significant near-term clinical evidence catalyst in the retrieved dataset. Its results will clarify the clinical relevance of the noradrenergic/serotonergic axis in HG and inform future combination trial design.

Cannabinoids and Endocannabinoid Biology

A small observational study (n=4) from the Motherisk Program at Ariel University evaluated cannabis use in HG using the validated PUQE scoring system. Cannabis produced a statistically significant improvement in PUQE score from 14.5 ± 1 to 7.5 ± 0.58 (p=0.0004) alongside quality of life improvements. While the sample size limits generalisability, the mechanistic alignment is coherent: a systematic review from Umeå University (2020) found that free fatty acids, lipid profiles, and bioactive lipids — including prostaglandin E2 and endocannabinoids — are altered in HG, providing molecular support for cannabinoid receptor modulation as a therapeutic strategy. The cannabinoid signal in refractory HG is scientifically coherent but clinically underpowered, and a controlled trial of a pregnancy-safe cannabinoid formulation would require engagement with obstetric safety frameworks given fetal exposure concerns.

ADAMTS-1: A Novel Biomarker Candidate

A 2022 cross-sectional study from Balikesir University (n=45 HG vs. n=44 controls) identified elevated ADAMTS-1 levels in HG patients compared to healthy pregnant controls. ADAMTS-1 is a protease secreted during trophoblastic invasion, and its elevation in HG may reflect altered placental remodelling. The HG group also showed elevated inflammatory markers including neutrophil count, MPV, PDW, and PCT. No therapeutic intervention targeting ADAMTS-1 in HG was retrieved; it currently represents a candidate biomarker and potential mechanistic node linking placental biology to HG pathophysiology, according to NIH-indexed research in this domain.

Thalidomide Pharmacology as a Drug Discovery Framework

A 2022 review from St. George’s University of London surveys thalidomide’s anti-emetic evidence and mechanistic pharmacology — including TNF-α inhibition, PDE4 inhibition, H1 blockade, and sedative effects — as a translational framework for identifying pregnancy-safe analogs. Thalidomide itself is not a viable therapeutic candidate in pregnancy given its well-documented teratogenicity; however, the mechanistic review offers a scaffold for drug discovery efforts targeting inflammatory and serotonergic pathways in HG.

Pipeline Landscape: Clinical Signals and IP Implications

The HG drug pipeline, as captured in the retrieved dataset, is composed entirely of academic literature with no patent filings directly describing HG-specific therapeutics — a striking contrast to adjacent pregnancy complication fields such as preeclampsia, which show dense patent activity. This academic-only character signals that the commercial IP landscape for targeted HG therapies, particularly GDF15 antagonists, is either early-stage or concentrated in patent families not yet retrieved — representing a significant due diligence gap for IP strategists and drug developers.

The institutional landscape is distributed across three functional clusters. GDF15 biology and genetics research is anchored at the Wellcome Trust-MRC Institute of Metabolic Science at the University of Cambridge (Cambridge Baby Growth Study, 2017) and the David Geffen School of Medicine at UCLA (familial HG genetics, 2018). Clinical pharmacotherapy evaluation is led by Haukeland University Hospital, Norway; the Hashemite University, Jordan; and Nordsjaellands Hospital, Denmark (VOMIT trial). Mechanistic and biomarker research spans Balikesir University (Turkey), Umeå University (Sweden), Ariel University (Israel), and the University of Otago (New Zealand).

Key clinical evidence signals in the retrieved dataset include: the VOMIT trial (n=180 planned, eight Danish hospitals, active RCT); the ondansetron vs. metoclopramide meta-analysis (five pooled RCTs, n=695); the Norwegian retrospective cohort (2002–2019, n=1,064); the prednisolone RCT (n=300); the acupressure RCT (n=90); and the Cambridge GDF15 serum study (n=791). No retrieved result reports regulatory approval of a GDF15-targeted therapy for HG, nor are any completed phase II/III trial results for such an agent described. According to WHO frameworks for maternal health drug development, conditions affecting pregnant women with significant morbidity and limited treatment options represent priority areas for clinical investigation — a categorisation that aligns directly with the HG therapeutic gap.

The non-pharmacological evidence base includes an acupressure RCT (n=90, tertiary hospital Malaysia) comparing P6 point stimulation versus intravenous antiemetics using modified PUQE scores as the primary outcome, and percutaneous endoscopic jejunostomy (PEG-J) tube placement documented as a last-resort nutritional support approach for refractory HG. These modalities represent the current clinical ceiling for patients who do not respond to pharmacotherapy, underscoring the unmet need for mechanism-targeted agents. The EMA‘s 2013 restrictions on metoclopramide further constrain the available therapeutic toolkit, reinforcing the commercial opportunity for any agent demonstrating superior efficacy in a well-powered HG trial.

Strategic Implications for Drug Developers and IP Strategists

GDF15/GFRAL is the highest-value mechanistic target in the HG pipeline based on the retrieved dataset. The convergence of large-scale serum biomarker evidence (n=791, Cambridge), familial exome genetics (UCLA), and hindbrain-specific receptor expression creates a compelling translational basis for anti-GDF15 or anti-GFRAL monoclonal antibodies. The absence of HG-specific patent filings in the retrieved dataset is a significant signal: it suggests the commercial IP landscape is either early-stage or concentrated in patent families not captured — a due diligence gap worth addressing for IP strategists and licensing teams.

The pharmacotherapeutic standard of care for HG remains symptomatic and evidence-poor. Retrieved results highlight that existing treatments — metoclopramide, ondansetron, corticosteroids — lack strong RCT support in HG specifically, creating a regulatory and commercial opportunity for any agent that can demonstrate superior efficacy in a well-powered trial with validated endpoints such as the PUQE score. The VOMIT trial (mirtazapine vs. ondansetron vs. placebo, n=180) is the most significant near-term clinical evidence catalyst, and its results will inform both future combination trial design and labelling strategies for the noradrenergic/serotonergic axis in HG.

“The academic-only character of the HG therapeutic pipeline — contrasted with dense patent activity in adjacent pregnancy complication fields — underscores that GDF15 antagonism in HG represents an IP-nascent but scientifically mature opportunity.”

Five strategic directions emerge from the retrieved evidence base. First, anti-GDF15 or anti-GFRAL antibody development for HG represents the highest-potential mechanistic opportunity, with IND-enabling biomarker data (Cambridge, n=791) already available. Second, CYP2D6 genotyping before metoclopramide prescription is a clinical implementation-ready precision medicine signal requiring no new drug development. Third, the VOMIT trial results will be a critical decision point for mirtazapine’s role in HG combination regimens. Fourth, a controlled trial of a pregnancy-safe cannabinoid formulation in refractory HG is scientifically justified by the PUQE data and endocannabinoid biology, pending obstetric safety framework engagement. Fifth, ADAMTS-1 represents a nascent biomarker candidate for patient stratification in future HG trials, as noted in research indexed by PubMed/NIH.

For IP strategists, the absence of retrieved HG-specific patent filings on GDF15 antagonism should prompt a targeted freedom-to-operate analysis across broader GFRAL and GDF15 antibody patent families — including those filed for oncology, cachexia, and metabolic indications where GDF15/GFRAL biology has attracted commercial interest. The PatSnap Life Sciences platform provides cross-indication patent landscape analysis that can map GDF15 antibody IP across therapeutic areas, enabling developers to identify white-space opportunities and potential blocking patents before entering the HG indication. The PatSnap Insights blog regularly publishes drug pipeline analyses across maternal health and rare disease indications.